OsteoMed v. Stryker: Federal Circuit Issues Split Ruling on Bone Plate Patent
OsteoMed, LLC appealed against Stryker Corporation and Wright Medical Technology over US10245085B2, a patent covering bone plates with transfixation screw holes. The Federal Circuit issued a three-way split decision — affirming, vacating and remanding, and reversing in part — across an 850-day appellate proceeding.
Federal Circuit splits the verdict across three distinct outcomes
OsteoMed, LLC filed Case No. 23-1979 at the Court of Appeals for the Federal Circuit on 6 June 2023, challenging an earlier ruling concerning US10245085B2 — a patent protecting a bone plate incorporating a transfixation screw hole, a structural element central to orthopaedic fixation procedures. The defendants, Stryker Corporation and its subsidiary Wright Medical Technology, Inc., had successfully challenged the patent’s validity at the lower tribunal level under an invalidity/cancellation action.
The Federal Circuit closed the case on 3 October 2025 with a three-part disposition: certain claims or issues were affirmed, confirming the lower tribunal’s findings on those points; other elements were vacated and remanded, nullifying those specific conclusions and directing further proceedings; and a remaining portion was reversed outright, overturning the tribunal below on those issues. The appeal was also dismissed in part, suggesting some grounds were not reached on the merits.
At 850 days, this appeal ran considerably longer than typical Federal Circuit patentability cases, which may reflect the technical complexity of the claim-by-claim analysis or the breadth of issues raised across multiple patent claims. The mixed outcome — unusual in its three-part structure — suggests the court found merit in OsteoMed’s position on at least some challenged claims while declining to disturb other adverse findings. The precise claim-by-claim mapping of each disposition element is not fully apparent from the public record.
Filing to Appeal Dismissed in Part in 850 days
850 days — extended appellate timeline, above typical Federal Circuit resolution benchmarks
Federal Circuit’s split ruling: what each part of the decision means
A three-part appellate disposition is uncommon — here’s what it means
The Federal Circuit’s affirmed-in-part, vacated-and-remanded-in-part, reversed-in-part ruling reflects a granular, claim-level analysis. ‘Affirmed’ means no reversible error was found on those issues. ‘Vacated and remanded’ nullifies specific lower findings and sends them back for reconsideration. ‘Reversed’ directly overturns the lower tribunal on discrete points. The partial dismissal suggests some grounds were not reached on the merits.
Claim-by-claim appellate scrutinyOsteoMed secures partial reinstatement — some claims survive or return
The reversal-in-part and vacatur-in-part outcomes are meaningful wins for OsteoMed. Reversed findings indicate the Federal Circuit disagreed with the lower tribunal’s invalidity conclusions on those specific issues, restoring OsteoMed’s position. Remanded issues give OsteoMed a further opportunity to prevail. However, affirmed portions confirm that certain adverse findings against US10245085B2 will stand, limiting full reinstatement.
Partial patent reinstatementStryker retains some invalidity wins but faces renewed proceedings
Stryker Corporation and Wright Medical Technology preserve their victories on the affirmed portion, meaning selected invalidity findings against US10245085B2 remain intact. However, the reversal-in-part and remand expose them to further proceedings on multiple claim groups. The remanded issues in particular require Stryker to re-engage before the lower tribunal, extending the overall dispute timeline and increasing litigation cost exposure.
Partial invalidity findings preservedMixed ruling sustains uncertainty in orthopaedic fixation IP landscape
For the broader orthopaedic device sector, this outcome signals that bone plate transfixation screw technology remains a contested IP space. The partial reversal strengthens OsteoMed’s enforcement posture on surviving claims, while the remand creates a continuing cloud of uncertainty for competing products. Device manufacturers active in bone fixation should reassess freedom-to-operate positions against US10245085B2 pending resolution of remanded issues.
Ongoing FTO risk for bone fixation devicesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | OsteoMed, LLC | Company | Orthopaedic IP licensing entity — holder of US10245085B2 (bone plate transfixation technology)Search in Eureka ↗ |
| Defendant | Stryker Corporation | Company | Stryker Corporation and Wright Medical Technology, Inc. — global orthopaedic device manufacturersSearch in Eureka ↗ |
| Co-Defendant | Wright Medical Technology, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Devon C. Beane | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Jonah Heemstra | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Alston & Bird LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Arnold & Porter Kaye Scholer LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Defendant counsel | Sharon Hwang | Attorney | Counsel for Stryker CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition — ‘AFFIRMED-IN-PART, VACATED AND REMANDED-IN-PART, REVERSED-IN-PART’ — reflects individuated review of discrete claim and issue groupings rather than a wholesale disposition. Under Federal Circuit appellate standards, affirmance requires absence of reversible legal error or substantial evidence support for factual findings; reversal denotes identified legal error or unsupported fact-finding below; vacatur with remand signals the lower tribunal must reconsider specific issues under corrected legal standards. The partial dismissal further narrows the scope of issues fully adjudicated on the merits.
US10245085B2 — Bone Plate with Transfixation Screw Hole
US10245085B2, filed under application number US15/707891, protects a bone plate design that incorporates a transfixation screw hole — a structural configuration allowing a fixation screw to pass through and lock across bone segments. This technology is relevant to foot and ankle orthopaedic surgery, where precise bone fixation geometry is critical to post-operative outcomes. The patent’s claims define specific structural relationships that distinguish the design from earlier fixation plate art.
Given the involvement of Stryker Corporation and Wright Medical Technology — two of the most significant global players in foot and ankle surgical instrumentation — this patent represents a commercially meaningful asset in a high-value surgical device segment. OsteoMed’s enforcement posture, now partially vindicated at the Federal Circuit, suggests the patent family retains licensing and exclusionary value. Competing manufacturers of bone fixation plates should treat the surviving and remanded claims of US10245085B2 as live enforcement risk.
Should you run an FTO against US10245085B2?
Any company designing, manufacturing, or distributing bone plates with transfixation screw hole configurations — particularly in the foot, ankle, and small bone fixation market — should treat US10245085B2 as an active clearance concern. The Federal Circuit’s partial reversal means claims previously considered invalid may now be enforceable, and remanded claims remain in legal limbo. Existing FTO opinions based on pre-appeal validity assessments may no longer be reliable.
PatSnap Eureka’s FTO Search Agent can map the specific structural claim language of US10245085B2 against your product design parameters, identify which claim groups were affirmed invalid versus reversed or remanded, and flag related continuation or family patents that may extend OsteoMed’s coverage. Start with a targeted claim-level search to understand your current exposure before remand proceedings conclude.
Run a freedom-to-operate analysis on US10245085B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Orthopaedic Device Patent Appeals
Explore related Federal Circuit invalidity appeals involving orthopaedic fixation patents, bone plate technology, and surgical device patentability challenges.
What this case signals for the orthopaedic device IP landscape
A split Federal Circuit ruling on bone plate patents raises the enforcement stakes for the entire orthopaedic fixation sector.
Partial reversals at the Federal Circuit revive enforcement leverage
Even a partial reversal at the Federal Circuit is commercially significant. OsteoMed’s restored claim positions may support renewed licensing pressure against manufacturers of competing bone plate products. Companies that assumed the patent was fully invalidated should immediately reassess that position.
Remanded claims keep competitors in prolonged legal uncertainty
Remanded patent claims return to the lower tribunal for fresh analysis, meaning the dispute is not concluded. Orthopaedic device manufacturers — particularly those with products relying on transfixation screw hole configurations — face a material period of unresolved risk that could affect product launch and investment decisions.
OsteoMed v Stryker — key questions answered
The Federal Circuit issued a split decision: affirmed-in-part, vacated and remanded-in-part, and reversed-in-part. This means the court upheld some lower tribunal findings on US10245085B2, nullified and sent back others for reconsideration, and directly overturned remaining findings. The appeal was also dismissed in part.
US10245085B2, filed as application US15/707891, covers a bone plate incorporating a transfixation screw hole — a surgical fixation device used in orthopaedic procedures, particularly in foot and ankle surgery. The patent’s structural claims were the subject of the invalidity/cancellation challenge brought by Stryker and Wright Medical Technology.
Vacatur means the Federal Circuit nullified specific lower tribunal findings on those claim groups — those determinations no longer stand. Remand means those issues are sent back to the lower tribunal for reconsideration under the correct legal standards. Practically, remanded claims remain in an unresolved state and continue to represent both enforcement opportunity for OsteoMed and legal risk for competitors.
Not entirely. The reversal-in-part means OsteoMed prevailed on specific issues — the Federal Circuit found error in the lower tribunal’s adverse rulings on those points. However, the affirmed portion means Stryker retains certain invalidity findings. The outcome is a partial win for both sides, with continued proceedings expected on remanded issues.
Yes. The Federal Circuit’s mixed ruling changes the validity landscape for US10245085B2. Claims previously assumed invalid based on lower tribunal findings may now be enforceable following reversal, while remanded claims remain unsettled. Any existing FTO opinion that relied on pre-appeal invalidity conclusions should be reviewed and potentially updated before commercialising products in the bone plate fixation space.
PatSnap Eureka searches patents and litigation data to answer instantly.